INTRODUCTION: Comprehensive approaches for patients with psychotic symptoms play essential roles in the symptomatic and functional outcomes of patients, especially during disease onset. In Japan, the shortage of mental health services, particularly for outpatients, and community-based supports has been a major problem. The purpose of this trial is to investigate the effectiveness and affordability of 18-month comprehensive early intervention services for patients with first-episode psychosis compared with typical treatment. METHODS: This interventional, parallel, single-blinded (open but blinded raters trial) was effectively designed. The participants are patients with a diagnosis of F2 or F3 (International Classification of Disease, 10 th revision), with psychotic symptoms. The inclusion criteria were an age of 15-35 years, onset of psychotic symptoms within 5 years, first-episode psychosis, and residence in the catchment area of each site. Allocation will be conducted equally between case management and standard care groups. After enrollment, standard care will be provided for both groups, and community-based care to promote recovery for 18 months will be provided for the comprehensive approach group. The primary outcome will be the function domain of the global assessment of functioning scores at 18 months after enrollment. Data assessment will be performed at enrollment and 18, 36, and 60 months after enrollment. The target sample size will be 150, and registration will occur from March 1, 2011, to September 30, 2012. DISCUSSION: This trial will provide promising results about the effectiveness and cost-effectiveness of early intervention services in Japan to improve the quality and quantity of community mental health services. TRIAL REGISTRATION: This trial was registered in The University Hospital Medical Information Network Clinical Trials Registry (No. UMIN000005092).
RCT Entities:
INTRODUCTION: Comprehensive approaches for patients with psychotic symptoms play essential roles in the symptomatic and functional outcomes of patients, especially during disease onset. In Japan, the shortage of mental health services, particularly for outpatients, and community-based supports has been a major problem. The purpose of this trial is to investigate the effectiveness and affordability of 18-month comprehensive early intervention services for patients with first-episode psychosis compared with typical treatment. METHODS: This interventional, parallel, single-blinded (open but blinded raters trial) was effectively designed. The participants are patients with a diagnosis of F2 or F3 (International Classification of Disease, 10 th revision), with psychotic symptoms. The inclusion criteria were an age of 15-35 years, onset of psychotic symptoms within 5 years, first-episode psychosis, and residence in the catchment area of each site. Allocation will be conducted equally between case management and standard care groups. After enrollment, standard care will be provided for both groups, and community-based care to promote recovery for 18 months will be provided for the comprehensive approach group. The primary outcome will be the function domain of the global assessment of functioning scores at 18 months after enrollment. Data assessment will be performed at enrollment and 18, 36, and 60 months after enrollment. The target sample size will be 150, and registration will occur from March 1, 2011, to September 30, 2012. DISCUSSION: This trial will provide promising results about the effectiveness and cost-effectiveness of early intervention services in Japan to improve the quality and quantity of community mental health services. TRIAL REGISTRATION: This trial was registered in The University Hospital Medical Information Network Clinical Trials Registry (No. UMIN000005092).
Authors: Philippa A Garety; Tom K J Craig; Graham Dunn; Miriam Fornells-Ambrojo; Susannah Colbert; Nikola Rahaman; Jason Read; Jason Reed; Paddy Power Journal: Br J Psychiatry Date: 2006-01 Impact factor: 9.319
Authors: Nancy C Andreasen; William T Carpenter; John M Kane; Robert A Lasser; Stephen R Marder; Daniel R Weinberger Journal: Am J Psychiatry Date: 2005-03 Impact factor: 18.112
Authors: Tom K J Craig; Philippa Garety; Paddy Power; Nikola Rahaman; Susannah Colbert; Miriam Fornells-Ambrojo; Graham Dunn Journal: BMJ Date: 2004-10-14
Authors: Anthony P Morrison; Paul French; Lara Walford; Shôn W Lewis; Aoiffe Kilcommons; Joanne Green; Sophie Parker; Richard P Bentall Journal: Br J Psychiatry Date: 2004-10 Impact factor: 9.319
Authors: Christian R Dolder; Jonathan P Lacro; Kathleen A Warren; Shahrokh Golshan; Diana O Perkins; Dilip V Jeste Journal: J Clin Psychopharmacol Date: 2004-08 Impact factor: 3.153